Drugmaker Moderna Inc. sent out its first batch of a experimental coronavirus vaccine to be tested in humans; eptinezumab, sold as Vyepti and developed by Lundbeck, was approved by the FDA as a migraine prevention therapy; a US appeals court upheld a Trump administration rule on abortion referrals.
Yesterday, drugmaker Moderna Inc. shipped the first batch of its developed coronavirus vaccine to US government researchers who will then test its efficacy for the first time in a human cohort trial, according to The Wall Street Journal. The vaccine was rapidly developed by the manufacturers in 3 months and will be tested on 20-25 healthy volunteers in April to determine whether 2 doses will be safe and generate an immune response to protect against infection. Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said that results will be available in July or August.
Eptinezumab, sold as Vyepti and developed by drugmaker Lundbeck, was approved by the FDA as a migraine prevention therapy, adding to the available class of biologic drugs that are laboratory-produced molecules engineered to serve as substitute disease-fighting antibodies. Reuters reports that the drug will be administered via intravenous infusion; it works to inhibit the calcitonin gene-related peptide, a known catalyst for migraine pain development.
The US 9th Circuit Court of Appeals ruled Monday to uphold a 2019 Trump administration rule that denies family planning grants to clinics that make referrals for abortion, according to the Los Angeles Times. The decision additionally overturned injunctions issued by different judges in 3 Western states, including California. The split 7-4 party line ruling was an en banc review, which means all of the district court judges have a chance to weigh in on a previous decision rendered by a 3-judge panel. Since taking office, President Trump has been actively replacing federal judges with those with Republican backgrounds.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
2 Commerce Drive
Cranbury, NJ 08512